We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

New Blood Test Can Determine When an Individual Was Exposed to a Pathogenic Microorganism

By LabMedica International staff writers
Posted on 19 May 2020
Print article
Image: A new blood test has been developed for detecting recent exposure to `relapsing` or vivax malaria (Photo courtesy of Mayeta Clark, Walter and Eliza Hall Institute, Australia)
Image: A new blood test has been developed for detecting recent exposure to `relapsing` or vivax malaria (Photo courtesy of Mayeta Clark, Walter and Eliza Hall Institute, Australia)
An international research team has developed a diagnostic blood test – initially for the recurring form of vivax malaria – that can determine when an individual was exposed to a pathogenic microorganism, including the coronavirus that causes COVID-19.

Investigators at Walter and Eliza Hall Institute (Melbourne, Australia) and colleagues in France and Japan sought to develop a method for identification of individuals carrying clinically silent and undetectable liver-stage malaria parasites, called hypnozoites.

To this end, they developed a panel of serological exposure markers capable of classifying individuals with recent Plasmodium vivax infections who had a high likelihood of harboring hypnozoites. The investigators measured IgG antibody responses to 342 P. vivax proteins in longitudinal clinical cohorts conducted in Thailand and Brazil and identified candidate serological exposure markers.

Candidate markers were validated using samples from year-long observational cohorts conducted in Thailand, Brazil, and the Solomon Islands and antibody responses to eight P. vivax proteins were shown to characterize P. vivax infections that had occurred during the previous nine months with 80% sensitivity and specificity. These eight antibody responses could serve as a biomarker panel, identifying individuals who should be targeted with anti-hypnozoite therapy.

"Many tests for immunity give a simple “yes or no” answer to whether someone has antibodies to the infectious agent," said senior author Dr. Ivo Mueller, joint head of the division of population health and immunity at Walter and Eliza Hall Institute. "In contrast, our test - which was initially developed to look at malaria infections - can pinpoint how long ago a person was exposed to an infection. This information is extremely valuable for tracking the spread of an infection in a population. Particularly in lower income countries it may not be possible to monitor the actual spread of the infection, but it is very helpful to look retrospectively at whether the infection has been spreading - and to monitor the effectiveness of infection control programs, and respond to disease resurgence. We will be working with the Australian biotech company Axxin (Fairfield, Australia) to develop a diagnostic test for malaria that can be deployed in the field, based on the immune markers our laboratory testing identified."

Dr. Mueller said, "We have already started to study the blood of people who have had COVID-19 infections to document the types of antibodies they carry. In the next six months we hope to have discovered how these antibodies change over time, meaning we can use this information to explore immunity in wider groups in the community. This is not a tool for diagnosing individual people, but rather for monitoring COVID-19 disease spread in populations."

The malaria antibody test was described in the May 11, 2020, online edition of the journal Nature Medicine.

Related Links:
Walter and Eliza Hall Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.